$5.6
0.54%
Downside
Day's Volatility :3.63%
Upside
3.11%
43.57%
Downside
52 Weeks Volatility :68.81%
Upside
44.72%
Period | Ardelyx Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -13.18% | 5.1% | 0.0% |
6 Months | -37.57% | 4.9% | 0.0% |
1 Year | 23.35% | 16.6% | 0.0% |
3 Years | 300.0% | 13.2% | -22.3% |
Market Capitalization | 1.3B |
Book Value | $0.62 |
Earnings Per Share (EPS) | -0.27 |
PEG Ratio | -0.08 |
Wall Street Target Price | 11.65 |
Profit Margin | -31.02% |
Operating Margin TTM | -18.62% |
Return On Assets TTM | -13.27% |
Return On Equity TTM | -48.23% |
Revenue TTM | 210.0M |
Revenue Per Share TTM | 0.91 |
Quarterly Revenue Growth YOY | 227.89999999999998% |
Gross Profit TTM | 15.5M |
EBITDA | -57.2M |
Diluted Eps TTM | -0.27 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.27 |
EPS Estimate Next Year | -0.12 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | -0.08 |
What analysts predicted
Upside of 108.04%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.6M | ↓ 93.79% |
Net Income | -91.3M | ↑ 41.9% |
Net Profit Margin | -3.5K% | ↓ 3348.84% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 5.3M | ↑ 102.57% |
Net Income | -94.9M | ↑ 3.99% |
Net Profit Margin | -1.8K% | ↑ 1704.26% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.6M | ↑ 43.36% |
Net Income | -94.3M | ↓ 0.66% |
Net Profit Margin | -1.2K% | ↑ 552.06% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 10.1M | ↑ 33.36% |
Net Income | -158.2M | ↑ 67.7% |
Net Profit Margin | -1.6K% | ↓ 320.75% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 52.2M | ↑ 416.57% |
Net Income | -67.2M | ↓ 57.51% |
Net Profit Margin | -128.85% | ↑ 1437.61% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 124.5M | ↑ 138.61% |
Net Income | -66.1M | ↓ 1.7% |
Net Profit Margin | -53.08% | ↑ 75.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.4M | ↓ 74.27% |
Net Income | -26.8M | ↓ 350.33% |
Net Profit Margin | -235.49% | ↓ 259.7% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.3M | ↑ 96.44% |
Net Income | -17.1M | ↓ 36.05% |
Net Profit Margin | -76.66% | ↑ 158.83% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 56.4M | ↑ 152.5% |
Net Income | 6.6M | ↓ 138.72% |
Net Profit Margin | 11.76% | ↑ 88.42% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 34.4M | ↓ 39.06% |
Net Income | -28.8M | ↓ 534.48% |
Net Profit Margin | -83.82% | ↓ 95.58% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 46.0M | ↑ 33.93% |
Net Income | -26.5M | ↓ 7.93% |
Net Profit Margin | -57.62% | ↑ 26.2% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 73.2M | ↑ 59.1% |
Net Income | -16.5M | ↓ 37.95% |
Net Profit Margin | -22.47% | ↑ 35.15% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 183.3M | ↑ 16.1% |
Total Liabilities | 67.5M | ↑ 263.18% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 259.8M | ↑ 41.7% |
Total Liabilities | 73.1M | ↑ 8.31% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 201.6M | ↓ 22.41% |
Total Liabilities | 75.5M | ↑ 3.18% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 149.9M | ↓ 25.62% |
Total Liabilities | 67.3M | ↓ 10.81% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 190.1M | ↑ 26.78% |
Total Liabilities | 91.7M | ↑ 36.32% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 297.6M | ↑ 56.57% |
Total Liabilities | 130.8M | ↑ 42.54% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 217.0M | ↑ 14.18% |
Total Liabilities | 91.6M | ↓ 0.15% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 211.2M | ↓ 2.68% |
Total Liabilities | 88.0M | ↓ 3.88% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 289.4M | ↑ 37.01% |
Total Liabilities | 98.2M | ↑ 11.56% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 297.6M | ↑ 2.83% |
Total Liabilities | 130.8M | ↑ 33.14% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 342.4M | ↑ 15.06% |
Total Liabilities | 191.5M | ↑ 46.44% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 343.5M | ↑ 0.32% |
Total Liabilities | 196.5M | ↑ 2.61% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -70.3M | ↑ 7.8% |
Investing Cash Flow | -29.9M | ↓ 145.79% |
Financing Cash Flow | 103.6M | ↑ 15017.23% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -76.5M | ↑ 8.84% |
Investing Cash Flow | 23.4M | ↓ 178.19% |
Financing Cash Flow | 155.5M | ↑ 50.14% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -81.4M | ↑ 6.47% |
Investing Cash Flow | -31.4M | ↓ 234.52% |
Financing Cash Flow | 22.8M | ↓ 85.35% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -152.6M | ↑ 87.33% |
Investing Cash Flow | 50.9M | ↓ 262.04% |
Financing Cash Flow | 83.0M | ↑ 264.41% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -70.0M | ↓ 54.08% |
Investing Cash Flow | 18.4M | ↓ 63.86% |
Financing Cash Flow | 75.3M | ↓ 9.23% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -44.8M | ↓ 413.6% |
Investing Cash Flow | -9.8M | ↓ 778.49% |
Financing Cash Flow | 50.9M | ↑ 171.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.7M | ↓ 67.1% |
Investing Cash Flow | -59.2M | ↑ 505.57% |
Financing Cash Flow | 11.5M | ↓ 77.39% |
Sell
Neutral
Buy
Ardelyx Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Ardelyx Inc | 0.9% | -37.57% | 23.35% | 300.0% | -0.36% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Ardelyx Inc | NA | NA | -0.08 | -0.27 | -0.48 | -0.13 | NA | 0.62 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Ardelyx Inc | Buy | $1.3B | -0.36% | NA | -31.02% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Ardelyx Inc
Revenue is up for the last 3 quarters, 34.36M → 73.22M (in $), with an average increase of 31.2% per quarter
Netprofit is up for the last 3 quarters, -28.80M → -16.45M (in $), with an average increase of 34.9% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 13.8%
HHG PLC
BlackRock Inc
State Street Corporation
Vanguard Group Inc
Eventide Asset Management, LLC
Geode Capital Management, LLC
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Organization | Ardelyx Inc |
Employees | 267 |
CEO | Mr. Michael G. Raab |
Industry | Health Technology |
A Spac I Acquisition Corp
$5.60
-2.95%
Keyarch Acquisition Corp
$5.60
-2.95%
Connexa Sports Technologies Inc
$5.60
-2.95%
Us Value Etf
$5.60
-2.95%
First Wave Biopharma Inc
$5.60
-2.95%
Global X Msci Next Emerging
$5.60
-2.95%
Fat Projects Acquisition Corp
$5.60
-2.95%
Capital Link Global Fintech
$5.60
-2.95%
Applied Uv Inc
$5.60
-2.95%